Manufacturer
Genentech
Pharmaceutical manufacturer based in United States
United States
- Products listed
- 76
- Molecules
- 37
- Therapy areas
- 7
Genentech is a pharmaceutical manufacturer based in United States. MedsAcross lists 76 of its products across 37 molecules, each with registers, packs and availability for export supply to licensed buyers.
- Country
- United States
- Indian manufacturer
- No
- Also listed as
- Genentech, Inc.
- US FDA labeler
- YesSource: openFDA NDC directory
Source from this manufacturer
We supply Genentech products through licensed channels, with the documents your regulator needs.
Oncology
25 presentations
| Medicine | Active ingredient | Register | Availability |
|---|---|---|---|
| Alecensa 150 mg capsuleOral | Alectinib | US FDA | Available on request |
| Avastin 100 mg/4 mL injectionIntravenous Cold chain | Bevacizumab | US FDA | Available on request |
| Avastin 400 mg/16 mL injectionIntravenous Cold chain | Bevacizumab | US FDA | Available on request |
| Columvi 10 mg/10 mL injectionIntravenous Cold chain | Glofitamab | US FDA | Available on request |
| Columvi 2.5 mg/2.5 mL injectionIntravenous Cold chain | Glofitamab | US FDA | Available on request |
| Cotellic 20 mg tabletOral | Cobimetinib | US FDA | Available on request |
| Erivedge 150 mg capsuleOral | Vismodegib | US FDA | Available on request |
| Gazyva 1000 mg/40 mL injectionIntravenous Cold chain | Obinutuzumab | US FDA | Available on request |
| Herceptin 150 mg/7.4 mL powder for injectionIntravenous Cold chain | Trastuzumab | US FDA | Available on request |
| Kadcyla 20 mg/mL powder for injectionIntravenous Cold chain | Trastuzumab emtansine | US FDA | Available on request |
| Lunsumio 1 mg/1 mL injectionIntravenous Cold chain | Mosunetuzumab | US FDA | Available on request |
| Lunsumio 30 mg/30 mL injectionIntravenous Cold chain | Mosunetuzumab | US FDA | Available on request |
| Lunsumio Velo 45 mg/1 mL injectionSubcutaneous Cold chain | Mosunetuzumab | US FDA | Available on request |
| Lunsumio Velo 5 mg/0.5 mL injectionSubcutaneous Cold chain | Mosunetuzumab | US FDA | Available on request |
| Perjeta 420 mg/14 mL injectionIntravenous Cold chain | Pertuzumab | US FDA | Available on request |
| Polivy 140 mg/7.52 mL powder for injectionIntravenous Cold chain | Polatuzumab vedotin | US FDA | Available on request |
| Polivy 30 mg/1.88 mL powder for injectionIntravenous Cold chain | Polatuzumab vedotin | US FDA | Available on request |
| Rituxan 100 mg/10 mL injectionIntravenous Cold chain | Rituximab | US FDA | Available on request |
| Rituxan 500 mg/50 mL injectionIntravenous Cold chain | Rituximab | US FDA | Available on request |
| Rozlytrek 100 mg capsuleOral | Entrectinib | US FDA | Available on request |
| Rozlytrek 200 mg capsuleOral | Entrectinib | US FDA | Available on request |
| Rozlytrek 50 mg oral pelletsOral | Entrectinib | US FDA | Available on request |
| Tecentriq 1200 mg/20 mL injectionIntravenous Cold chain | Atezolizumab | US FDA | Available on request |
| Tecentriq 840 mg/14 mL injectionIntravenous Cold chain | Atezolizumab | US FDA | Available on request |
| Zelboraf 240 mg tabletOral | Vemurafenib | US FDA | Available on request |
Immunology and transplant
15 presentations
| Medicine | Active ingredient | Register | Availability |
|---|---|---|---|
| Actemra 162 mg/0.9 mL injectionSubcutaneous Cold chain | Tocilizumab | US FDA | Available on request |
| Actemra 200 mg/10 mL injectionIntravenous Cold chain | Tocilizumab | US FDA | Available on request |
| Actemra 400 mg/20 mL injectionIntravenous Cold chain | Tocilizumab | US FDA | Available on request |
| Actemra 80 mg/4 mL injectionIntravenous Cold chain | Tocilizumab | US FDA | Available on request |
| Actemra ACTPen 162 mg/0.9 mL injectionSubcutaneous Cold chain | Tocilizumab | US FDA | Available on request |
| CellCept 200 mg/mL powder for oral suspensionOral | Mycophenolate | US FDA | Available on request |
| CellCept 250 mg capsuleOral | Mycophenolate | US FDA | Available on request |
| CellCept 500 mg tabletOral | Mycophenolate | US FDA | Available on request |
| CellCept 500 mg/20 mL powder for injectionIntravenous | Mycophenolate | US FDA | Available on request |
| Enspryng 120 mg/1 mL injectionSubcutaneous Cold chain | Satralizumab | US FDA | Available on request |
| Enspryng 180 mg/1.5 mL injectionSubcutaneous Cold chain | Satralizumab | US FDA | Available on request |
| Esbriet 267 mg tabletOral | Pirfenidone | US FDA | Available on request |
| Esbriet 801 mg tabletOral | Pirfenidone | US FDA | Available on request |
| Ocrevus 300 mg/10 mL injectionIntravenous Cold chain | Ocrelizumab | US FDA | Available on request |
| Piasky 340 mg/2 mL injectionSubcutaneous Cold chain | Crovalimab | US FDA | Available on request |
Haematology
9 presentations
| Medicine | Active ingredient | Register | Availability |
|---|---|---|---|
| Activase kit Cold chain | Alteplase | US FDA | Available on request |
| Cathflo Activase 2.2 mg/2 mL powder for injectionIntravenous | Alteplase | US FDA | Available on request |
| Hemlibra 105 mg/0.7 mL injectionSubcutaneous Cold chain | Emicizumab | US FDA | Available on request |
| Hemlibra 12 mg/0.4 mL injectionSubcutaneous Cold chain | Emicizumab | US FDA | Available on request |
| Hemlibra 150 mg/1 mL injectionSubcutaneous Cold chain | Emicizumab | US FDA | Available on request |
| Hemlibra 30 mg/1 mL injectionSubcutaneous Cold chain | Emicizumab | US FDA | Available on request |
| Hemlibra 300 mg/2 mL injectionSubcutaneous Cold chain | Emicizumab | US FDA | Available on request |
| Hemlibra 60 mg/0.4 mL injectionSubcutaneous Cold chain | Emicizumab | US FDA | Available on request |
| TNKase kit Cold chain | Tenecteplase | US FDA | Available on request |
Ophthalmology
4 presentations
| Medicine | Active ingredient | Register | Availability |
|---|---|---|---|
| Lucentis 0.3 mg/0.05 mL injectionIntravitreal Cold chain | Ranibizumab | US FDA | Available on request |
| Lucentis 0.5 mg/0.05 mL injectionIntravitreal Cold chain | Ranibizumab | US FDA | Available on request |
| Susvimo 100 mg/1 mL injectionIntravitreal Cold chain | Ranibizumab | US FDA | Available on request |
| Vabysmo 6 mg/0.05 mL injectionIntravitreal Cold chain | Faricimab | US FDA | Available on request |
Respiratory
4 presentations
| Medicine | Active ingredient | Register | Availability |
|---|---|---|---|
| Xolair 150 mg/1.2 mL injectionSubcutaneous Cold chain | Omalizumab | US FDA | Available on request |
| Xolair 300 mg/2 mL injectionSubcutaneous Cold chain | Omalizumab | US FDA | Available on request |
| Xolair PFS 150 mg/1 mL injectionSubcutaneous Cold chain | Omalizumab | US FDA | Available on request |
| Xolair PFS 75 mg/0.5 mL injectionSubcutaneous Cold chain | Omalizumab | US FDA | Available on request |
Rare diseases and enzyme replacement
2 presentations
| Medicine | Active ingredient | Register | Availability |
|---|---|---|---|
| Evrysdi 0.75 mg/mL powder for oral solutionOral | Risdiplam | US FDA | Available on request |
| Evrysdi 5 mg tabletOral | Risdiplam | US FDA | Available on request |
Other products
14 presentations
| Medicine | Active ingredient | Register | Availability |
|---|---|---|---|
| Herceptin Hylecta 10000 units/600 mg per 5 mL injectionSubcutaneous Cold chain | Hyaluronidase (human recombinant) and Trastuzumab | US FDA | Available on request |
| Itovebi 3 mg tabletOral | Inavolisib | US FDA | Available on request |
| Itovebi 9 mg tabletOral | Inavolisib | US FDA | Available on request |
| Ocrevus Zunovo 23000 units/920 mg per 23 mL injectionSubcutaneous Cold chain | Hyaluronidase (human recombinant) and Ocrelizumab | US FDA | Available on request |
| Phesgo 20000 units/600 mg/600 mg per 10 mL injectionSubcutaneous Cold chain | Hyaluronidase (human recombinant), Pertuzumab and Trastuzumab | US FDA | Available on request |
| Phesgo 30000 units/1200 mg/600 mg per 15 mL injectionSubcutaneous Cold chain | Hyaluronidase (human recombinant), Pertuzumab and Trastuzumab | US FDA | Available on request |
| Pulmozyme 1 mg/mL inhalation solutionInhalation Cold chain | Dornase alfa | US FDA | Available on request |
| Rituxan Hycela 2000 units/120 mg per mL injectionSubcutaneous Cold chain | Hyaluronidase (human recombinant) and Rituximab | US FDA | Available on request |
| Tecentriq Hybreza 1875 mg/30000 units per 15 mL injectionSubcutaneous Cold chain | Atezolizumab and Hyaluronidase (human recombinant) | US FDA | Available on request |
| Xofluza 30 mg oral suspensionOral | Baloxavir marboxil | US FDA | Available on request |
| Xofluza 40 mg tabletOral | Baloxavir marboxil | US FDA | Available on request |
| Xofluza 40 mg oral suspensionOral | Baloxavir marboxil | US FDA | Available on request |
| Xofluza 40 mg/20 mL oral solutionOral | Baloxavir marboxil | US FDA | Available on request |
| Xofluza 80 mg tabletOral | Baloxavir marboxil | US FDA | Available on request |
Molecules made
TocilizumabAlteplaseAlectinibBevacizumabMycophenolateGlofitamabCobimetinibSatralizumabVismodegibPirfenidoneRisdiplamObinutuzumabEmicizumabTrastuzumabHyaluronidase (human recombinant) and TrastuzumabInavolisibTrastuzumab emtansineRanibizumabMosunetuzumabOcrelizumabHyaluronidase (human recombinant) and OcrelizumabPertuzumabHyaluronidase (human recombinant), Pertuzumab and TrastuzumabCrovalimabPolatuzumab vedotinDornase alfaRituximabHyaluronidase (human recombinant) and RituximabEntrectinibOseltamivirAtezolizumabAtezolizumab and Hyaluronidase (human recombinant)TenecteplaseFaricimabBaloxavir marboxilOmalizumabVemurafenib
Manufacturer facts come from public registers and are shown with their source. Listing does not mean the manufacturer endorses MedsAcross.
Source from Genentech
Send a request for any of these products. We confirm the licensed source, documents and lead time.